TargetRich NGS Panels
New Expectations in Targeted Enrichment with a fast, scalable, single tube work flow.
• Low starting material - requires just 250 ng DNA
• Scalable - high multiplexing from 1 to 96 samples
• High sensitivity - needed for mixed cell populations
• Improved coverage uniformity for more efficient use of sequencer capacity
• High alignment translates into lower sequencing cost per targeted base pair
• Easy - single tube additive reaction, no special equipment
• Fast - single day work flow
• Customized design solutions to support every research need
TargetRich™ provides the specificity you have come to expect from a PCR-based solution with the sensitivity, coverage uniformity and high alignment needed for efficient next generation sequencing today.
TargetRich™ CRX - complete coverage of the coding regions in ten commonly mutated genes studied in cancer research (BRAF, EGFR, FLT3, JAK2, KIT, KRAS, PIK3CA, PTEN, TP53 and VEGFA). The proprietary enrichment method, Nested PatchPCR™, enables you to capture known and novel mutations.
TargetRich™ kits utilize a technology based upon Nested PatchPCR™ to enrich genomic regions of interest for next generation sequencing. The first cancer research kit, TargetRich CRX, targets 10 genes (BRAF, EGFR, FLT3, JAK2, KIT, KRAS, PIK3CA, PTEN, TP53 and VEGFA) comprised of over 160 exons with greater than 150 amplicons.
Targeting primers are designed to flank regions of interest and used for limited-cycle PCR. The primers are then enzymatically digested and the resulting targeted products are blunted. To achieve the high level of specificity, patch oligos are designed for the target ends, allowing for the ligation of universal adaptors and a protecting group to the amplicon ends. An enzymatic digestion is then employed to remove non-targeted amplicons, leaving targeted regions for universal amplification. Starting with 250 ng of genomic DNA, all target loci are amplified simultaneously in a single tube and prepared for sequencing. See AACR poster TargetRich™ Cancer Gene Panels: Targeted Next Generation Sequencing in Cancer Samples.
|TargetRich CRX Cancer Research Panel for Illumina||CR104-KA||10 rxns||1850 €||DETAILS|
|TargetRich CRX Cancer Research Panel for Illumina||CR105-KA||96 rxns||11950 €||DETAILS|